hepat
b
viru
hbv
infect
one
major
threat
public
health
worldwid
chines
popul
suffer
chronic
hbv
infect
individu
approxim
develop
diseas
includ
liver
failur
cirrhosi
hepatocellular
carcinoma
hcc
nowaday
hcc
second
lead
caus
cancer
relat
death
china
base
comparison
hbv
genom
sequenc
eight
genotyp
hbv
h
classifi
genotyp
distinct
geograph
distribut
genotyp
higher
preval
europ
north
america
wherea
genotyp
b
c
preval
east
asia
includ
china
japan
countri
south
asia
china
genotyp
c
b
account
approxim
infect
individu
respect
wherea
genotyp
rare
patient
genotyp
c
hbv
greater
risk
advanc
hcc
genotyp
interferon
ifn
famili
cytokin
produc
mammalian
cell
invad
virus
depend
cellular
origin
stimulu
natur
antigen
specif
two
major
class
ifn
human
design
type
ifn
type
ii
ifn
contain
multipl
subtyp
normalhealthi
condit
low
level
ifn
express
yet
increas
bodi
attack
viral
infect
expos
rna
therefor
ifn
consid
natur
medic
resourc
antivir
agent
sinc
howev
due
high
cost
develop
approv
food
drug
administr
wide
appli
therapeut
use
specif
type
leukemia
multipl
sclerosi
hepat
b
c
genit
wart
cancer
contrari
expect
level
ifn
found
extrem
low
even
undetect
chronic
hbv
patient
routin
use
antivir
agent
treat
chronic
hbv
chb
infect
last
two
decad
unfortun
therapeut
outcom
mani
asian
patient
account
chb
carrier
infect
genotyp
b
c
viru
far
satisfactori
found
genotyp
b
c
hbv
predispos
patient
higher
risk
complic
includ
liver
cirrhosi
hcc
sever
factor
includ
short
limit
possibl
dosag
low
local
hepat
concentr
ifn
may
caus
therapeut
ineffici
hand
ifn
mani
subtyp
bear
differ
specif
efficaci
virus
shown
chb
patient
genotyp
respond
treatment
markedli
better
genotyp
c
antivir
effect
subtyp
genotyp
c
hbv
yet
test
previou
studi
demonstr
coronaviru
activ
stronger
et
al
unpublish
data
therefor
worthwhil
investig
activ
particularli
genotyp
c
viru
viru
aav
nonpathogen
human
parvoviru
kb
genom
recombin
aav
raav
recogn
one
promis
vector
deliveri
therapeut
gene
previou
studi
raav
shown
induc
low
inflammatori
respons
transduc
divid
nondivid
cell
sustain
express
vivo
usa
use
vector
phase
ii
clinic
trial
differ
diseas
confirm
feasibl
toler
absenc
undesir
trial
group
sinc
hbv
infect
human
be
chimpanze
vivo
cell
cultur
experi
wide
use
investig
hbv
virolog
screen
drug
gener
consist
reproduc
high
level
hbv
tetracyclin
control
cell
line
recogn
good
model
mimic
chb
infect
recent
hydrodynam
transfect
mous
model
develop
studi
present
studi
adopt
cell
line
hydrodynam
transfect
mice
investig
inhibit
abil
prolong
express
vitro
vivo
cell
grown
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
sigma
st
loui
mo
usa
penicillinstreptomycin
glutamin
incub
co
cell
medium
suppli
tetracyclin
begin
assay
confluent
cell
wash
prewarm
salin
pb
fed
medium
without
tetracyclin
replic
hbv
cell
facilit
withdraw
tetracyclin
cultur
media
cdna
encod
human
amplifi
revers
chain
reaction
use
total
rna
isol
peripher
blood
mononuclear
cell
chines
patient
primer
forward
revers
purifi
pcr
product
insert
vector
confirm
dna
sequenc
green
fluoresc
protein
egfp
vector
use
control
raav
vector
produc
hek
cell
use
helper
system
raav
purifi
previous
describ
minor
modif
viral
genom
copi
gc
determin
quantit
pcr
qpcr
carri
set
primer
probe
target
woodchuck
hbv
whbv
posttranscript
regulatori
element
wpre
region
primer
use
qpcr
reaction
forward
revers
probe
pcr
reaction
carri
use
abi
real
time
pcr
machin
appli
biosystem
foster
citi
ca
usa
aliquot
viral
stock
gcsml
store
use
measur
transduct
effici
cell
transfect
gc
per
cell
correspond
fluoresc
signal
captur
record
use
fluoresc
microscop
cell
harvest
differ
time
point
ie
h
raav
infect
electrophoresi
blot
perform
describ
previous
briefli
standard
amount
cell
extract
separ
use
transfer
onto
poli
vinyliden
difluorid
membran
incub
monoclon
antibodi
human
calbiochem
darmstadt
germani
hbsag
hbeag
measur
elisa
use
murex
hbsag
version
kit
abbott
murex
dartford
uk
accord
manufactur
instruct
dna
hbv
cultur
cell
isol
viral
particl
quantifi
qpcr
describ
previous
ethic
approv
obtain
univers
ethic
committe
uec
anim
taken
care
treat
accord
guidanc
uec
use
femal
balbc
nude
mice
mice
divid
three
group
six
mice
per
group
one
group
administr
pb
two
vector
respect
later
group
treatment
made
inject
gc
aav
tail
vein
one
week
later
phbv
adr
subtyp
genotyp
c
inject
tail
vein
mous
inject
volum
equival
bodi
mass
ie
ml
mous
g
total
volum
deliv
within
day
blood
sampl
collect
determin
express
level
surfac
e
antigen
well
viral
genom
dna
employ
protocol
describ
previous
liver
tissu
cell
fix
paraformaldehyd
direct
observ
egfp
perform
fluoresc
microscop
examin
express
level
hbsag
sampl
treat
triton
pb
anoth
min
expos
hydrogen
peroxid
methanol
min
block
normal
bovin
serum
incub
primari
monoclon
antibodi
hbsag
zyme
laboratori
san
francisco
ca
usa
hybrid
fitc
conjug
secondari
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
usa
imag
photograph
student
use
comparison
result
display
mean
sd
p
consid
statist
signific
insert
cdna
encod
multipl
clone
site
vector
gener
cotransfect
plasmid
express
enhanc
green
fluoresc
protein
aav
packag
vector
pdg
cell
produc
raav
vector
determin
transduct
effici
infect
cell
vector
gc
per
cell
note
transduct
effici
egfp
express
level
dramat
elev
increas
viral
vector
level
gcscell
increas
cell
display
strong
fluoresc
h
strong
fluoresc
could
last
sever
passag
data
shown
examin
express
level
cell
growth
medium
differ
time
point
western
blot
elisa
result
indic
extracellular
cultur
media
figur
intracellular
figur
appear
h
express
level
extracellular
remain
unchang
h
detect
protein
observ
cell
infect
vector
western
blot
analysi
concentr
cultur
media
significantli
increas
h
maintain
week
figur
concentr
reach
ngml
day
cultur
media
figur
investig
hbsag
hbeag
level
cell
administr
raav
vector
cell
transduc
raav
cultur
complet
media
without
tetracyclin
h
compar
cell
transduc
vector
mock
ie
nontransduc
hbsag
hbeag
level
significantli
reduc
cultur
media
cell
transduc
vector
day
day
n
p
figur
day
hbsag
hbeag
level
reduc
reduct
intracellular
hbsag
level
also
examin
confirm
use
immunocytochem
studi
data
shown
first
follow
protocol
describ
yang
et
al
establish
mous
model
studi
immunocompet
balbc
mice
hbsag
hbeag
level
plasma
peak
h
hydrodynam
transfect
plasmid
phbv
wherea
hbsag
hbeag
drop
rapidli
undetect
level
elisa
day
data
shown
indic
balbc
mice
suitabl
gene
therapi
studi
nude
mice
hbsag
hbeag
level
peak
h
administr
phbv
maintain
least
week
figur
thereaft
lower
level
hbsag
maintain
anoth
week
express
level
hbeag
similar
hbsag
figur
viral
load
remain
logsml
plasma
day
figur
nude
mice
support
longer
hbv
gene
express
replic
chosen
prove
principl
studi
transgen
express
level
liver
immunocompet
balbc
nude
mice
also
examin
shown
figur
group
egfp
strongli
express
respect
hepatocyt
near
blood
vessel
day
figur
maintain
similar
level
least
month
data
shown
consist
previou
find
contrast
neither
egfp
detect
group
also
obviou
liver
damag
necrosi
observ
group
reveal
hematoxylin
eosin
h
e
stain
figur
result
show
mean
valu
concentr
liver
higher
pgg
plasma
pgml
obviou
elev
alanin
aminotransaminas
alt
aspart
aminotransaminas
ast
activ
observ
group
figur
use
immunohistochem
assay
observ
hbsag
present
liver
group
wherea
faint
signal
detect
group
figur
also
use
elisa
examin
hbsag
hbeag
level
plasma
level
antigen
reduc
particularli
group
compar
pb
group
day
figur
p
day
detect
level
hbsag
hbeag
found
group
wherea
hbsag
still
remain
high
level
group
final
potenti
inhibit
hbv
replic
also
demonstr
viral
load
reach
logsml
plasma
pb
group
wherea
viral
load
log
group
day
viral
load
group
drop
log
day
day
log
day
signific
effect
observ
group
figur
compar
pb
group
mean
valu
viral
load
group
decreas
day
figur
wide
employ
combat
chronic
hbv
infect
worldwid
yet
clinic
outcom
unsatisfactori
especi
chines
patient
apart
frequent
repeat
inject
ifn
treatment
burden
patient
even
accord
previou
studi
effect
therapi
could
achiev
express
stabli
via
gene
transfer
although
vector
may
suitabl
human
gene
therapi
wherea
whbv
differ
human
hbv
result
suggest
gene
therapi
would
good
altern
treatment
present
studi
develop
vector
demonstr
therapeut
potenti
therapi
vector
use
extens
clinic
trial
demonstr
great
potenti
gene
therapi
applic
abil
mediat
transgen
express
liver
one
major
advantag
previou
studi
show
angiostatin
could
last
least
month
liver
immunocompet
mice
introduc
similar
observ
reveal
present
studi
could
last
least
month
liver
either
immunocompet
nude
mice
although
display
better
transduct
effici
hepatocyt
clinic
trial
data
concern
efficaci
safeti
avail
present
studi
better
transduct
ratio
ie
similar
achiev
administr
via
hydrodynam
transfect
figur
clinic
applic
drug
could
administr
portal
vein
local
perfus
extend
dwell
time
improv
therapeut
effect
eg
high
level
transduct
order
simul
clinic
condit
use
gene
deliveri
vector
present
studi
result
show
reduc
express
hbsag
hbeag
sustain
manner
suppress
viral
replic
without
detect
liver
toxic
figur
howev
obviou
delay
transgen
express
known
one
shortcom
studi
delay
egfp
ifn
express
note
egfp
express
level
transduct
effici
increas
elev
multipl
infect
wherea
strong
fluoresc
signal
last
sever
passag
data
shown
prolong
gene
express
mediat
raav
hepatocyt
observ
figur
furthermor
perform
raav
hydrodynam
transfect
phbv
plasmid
resolv
difficulti
import
anim
ie
hbv
transgen
mice
also
problem
gene
express
replic
hbv
hydrodynam
transfect
mous
model
present
studi
strong
egfp
signal
demonstr
liver
cell
figur
high
level
observ
liver
least
week
data
shown
concentr
liver
approxim
higher
plasma
sinc
ifn
short
ie
approxim
h
healthi
circul
system
repeat
inject
ifn
one
major
concern
sustain
level
ifn
liver
certainli
advantag
constant
prolong
local
express
ifn
would
sure
benefit
treatment
reduc
enhanc
efficaci
obviou
ifn
induct
toxic
observ
vitro
vivo
raav
appear
suitabl
vector
gene
transfer
deliveri
present
studi
intracellular
extracellular
antigen
significantli
reduc
transduct
hbsag
hbeag
level
significantli
decreas
cultur
media
find
prime
signific
minim
dosag
alreadi
achiev
similar
antivir
effect
unitsml
recombin
cell
moreov
antivir
effect
equival
commerci
avail
unitsml
isol
leukocyt
compos
multipl
interferon
isoform
see
supplementari
figur
drastic
decreas
ie
hbsag
hbeag
viral
load
ie
plasma
anoth
achiev
use
sinc
littl
effect
could
contribut
anim
immun
system
might
somewhat
stimul
biolog
mechan
vivo
synerg
antivir
activ
ifn
capabl
act
directli
ie
infect
cell
indirectli
ie
viral
infect
extend
innat
adapt
immun
respons
thu
boost
overal
antivir
abil
recent
year
use
short
hairpin
rna
shrna
target
hbv
transcript
becam
anoth
notabl
applic
aav
vector
major
advantag
shrna
display
target
one
design
multipl
effect
shrna
target
variou
transcript
previous
team
show
shrna
display
synergist
antivir
effect
lamuvidin
howev
compar
latter
offer
advantag
first
secret
protein
could
spread
one
cell
via
circul
effect
antivir
effect
could
easili
achiev
transduc
portion
liver
cell
use
vector
shrna
express
intracellular
manner
could
transfer
one
cell
anoth
limit
antivir
efficaci
increas
difficulti
gene
deliveri
effect
shrna
deliveri
one
major
concern
gene
therapi
second
efficaci
safeti
proven
clinic
decad
yet
issu
remain
elucid
micrornashrna
anim
studi
oversatur
cellular
micrornashrna
shown
lead
fatal
mice
therefor
safeti
issu
use
micrornashrna
base
gene
therapi
still
concern
team
investig
feasibl
vector
treatment
hbv
studi
obviou
liver
damag
mortal
observ
nude
mice
et
al
unpublish
data
howev
shrna
rapid
gener
mutant
rais
concern
respect
shrna
base
gene
therapi
taken
togeth
advantag
lack
resist
select
give
confid
propos
applic
vector
therapi
conclus
demonstr
vector
potenti
altern
therapi
flexibl
system
one
easili
also
test
isoform
ifn
therapeut
gene
well
shrna
variou
disord
colon
cancer
ifn
alreadi
use
clinic
treat
hcc
metastasi
moreov
use
synergi
drug
eg
nucleotid
analog
summ
antivir
effect
well
studi
find
provid
foundat
feasibl
use
vector
gene
therapi
combin
gene
therapi
chemotherapi
immunotherapi
hand
could
also
offer
better
antivir
effect
reduc
drug
dosag
nevertheless
investig
use
could
provid
benefit
beyond
chb
patient
sinc
system
might
promot
improv
clinic
outcom
diseas
